OSTX — OS Therapies Inc
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1795091 ·
Last close
$1.62
Market Cap
$75.82M
52W High
$2.25
52W Low
$1.15
ADV30
833,406
Next earnings
2026-11-16
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -8,575,612 | -8,632,386 | 9,897,313 | 205,035 | 21,811,948 |
| Mar 2026 | 0 | — | -10,167,938 | -10,396,831 | 7,299,236 | 917,552 | 18,123,474 |
| Dec 2025 | 0 | — | -11,987,892 | -13,460,833 | 6,839,534 | 269,830 | 12,935,165 |
| Sep 2025 | 0 | — | -6,879,595 | -6,879,530 | 8,953,251 | 1,876,626 | 5,316,056 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-15,360,230
Investing CF
$-292,787
Financing CF
$13,599,562
CapEx
$-466,423
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.85
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-77,583,050
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-35,198,472
Pretax Income TTM
$-35,273,816
Interest Exp TTM
$75,344
Analysts
5
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -28,705,701 | -28,753,844 | 6,839,534 | 12,935,165 | -6,095,631 | -14,238,576 |
| Dec 2024 | 0 | -6,813,846 | -8,882,938 | 5,538,797 | 8,805,335 | -3,266,538 | -7,282,295 |
| Dec 2023 | 0 | -4,342,645 | -7,791,582 | 798,082 | 24,814,297 | -24,016,215 | -3,006,967 |
| Dec 2022 | 0 | -4,446,299 | -6,254,685 | 509,105 | 18,066,333 | -17,557,228 | -3,792,580 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$228
NetIncome TTM
$-35,273,816
OpCashFlow TTM
—
Assets (Latest)
$7,299,236
Forward EPS
$0.35
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MNOV | MEDICINOVA INC | $75.80M | $1.54 | — |
| RFL | Rafael Holdings, Inc. | $75.79M | $1.48 | — |
| INCR | Intercure Ltd. | $75.47M | $5.03 | — |
| LFVN | Lifevantage Corp | $75.04M | $5.99 | — |
| NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. | $72.88M | $2.53 | — |
News headlines (Yahoo Finance, 1h cache)
Rubenstein Public Relations Named Agency of Record for OS Therapies
2026-10-08 13:22 · Yahoo
OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma
2026-10-07 12:30 · Yahoo
OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial
2026-10-06 12:30 · Yahoo
OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer
2026-10-01 12:30 · Yahoo
OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac)
2026-09-24 12:22 · Yahoo
OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis
2026-09-21 10:30 · Yahoo
OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program
2026-09-17 10:00 · Yahoo
OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing
2026-09-15 11:46 · Yahoo
OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial
2026-09-08 10:00 · Yahoo
OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance
2026-09-02 11:20 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.